PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ChemImage Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ChemImage Receives NIH Grant to Develop Blood Test for Early Detection of Colorectal Cancer - The National Cancer Institute has awarded a research grant (R43CA189585) to ChemImage Corporation to develop a blood test using its innovative technology based on high throughput Raman Molecular Imaging (RMI) spectroscopy - ChemImage.com
ChemImage Receives NIH Grant to Develop Blood Test for Early Detection of Colorectal Cancer

 

NewswireToday - /newswire/ - Pittsburgh, PA, United States, 2015/08/12 - The National Cancer Institute has awarded a research grant (R43CA189585) to ChemImage Corporation to develop a blood test using its innovative technology based on high throughput Raman Molecular Imaging (RMI) spectroscopy - ChemImage.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The National Cancer Institute, part of the National Institutes of Health (NIH), has awarded a research grant (R43CA189585) to ChemImage Corporation to develop a blood test using its innovative technology based on high throughput Raman Molecular Imaging (RMI) spectroscopy for colorectal cancer (CRC) diagnosis called the Raman Assay for Colorectal Cancer (RACC). The intended use of the RACC Test will be as an aid in screening, follow-up and diagnosis of patients for pre-cancerous polyps and colorectal cancer (CRC).

Scientists at ChemImage, in collaboration with Dr. Bergein Overholt of GastroIntestinal Associates (Knoxville, TN) and Dr. Paul Lebovitz of the Allegheny Health Network Center for Digestive Health (Pittsburgh, PA), anticipate undertaking the first demonstration of the technical feasibility of RACC applied to fresh clinical samples. The RACC Test, which is performed by collecting Raman Molecular images on dried blood serum samples, will provide clinical results to health care professionals who screen patients for CRC, including gastroenterologists, internal medicine and primary care physicians, once the RACC Test is validated and has received regulatory approvals.

"I am honored to collaborate with the team at ChemImage as we work to establish the clinical feasibility of RACC. The NIH grant is an important part of this work as it will allow us to make strides in our research for early detection of colorectal disease. We hope early detection through usage of the RACC Test will lead to improved patient outcomes in the future," said Dr. Overholt. In addition, Dr. Lebovitz said,"We have made great strides in detecting and treating colon cancer, but our gold standard of colonoscopy continues to be invasive and expensive. The work at ChemImage offers an opportunity to change the face of screening for colon cancer and moving to a time where we reach screening rates never seen before related to this preventative cancer. We are quite excited at the Allegheny Health Network to work on the trials with RACC and colon cancer screening and we believe we will see great success in the future."

In Pilot Studies, the RACC test has been able to detect subtle changes in dried blood serum composition and protein conformation without the use of chemical reagents. The RACC test has been shown to differentiate between bio-banked blood serum samples from patients with colorectal cancer versus those who are disease free with high sensitivity and specificity. Pilot Studies conducted to date suggest RACC is sensitive to early stage CRC and the presence of polyps, including advanced adenomas, and if validated as technically feasible RACC could have commercial value as a CRC screening in vitro diagnostic (IVD) assay.

"RACC has the potential to drive better utilization of colonoscopy if it continues to prove to have excellent detection performance at costs comparable to fecal occult blood tests, because it operates without the use of costly reagents," remarked Patrick J. Treado, Founder and Chief Technology Officer at ChemImage. "Because RACC would be applicable to blood serum samples, it is anticipated to have a very high compliance rate among target patient populations, and as a result improve the quality of care, and reduce the cost of managing colorectal disease."

If validated for the Intended Use as a CRC screening assay, RACC is expected in the future to undergo the Food and Drug Administration (FDA) premarket approval (PMA) process and will require approval from the Centers for Medicare & Medicaid Services (CMS) National Coverage Decision. ChemImage has assembled a Regulatory Affairs & Reimbursement Advisory Group, with participation of experienced consultants to guide this process. Overall, the company's Scientific Team, Clinical Advisory Board, Regulatory Affairs & Reimbursement Advisory Group are working to enhance the likelihood of successful clinical validation and commercialization.

For more information regarding ChemImage's Raman Molecular Imaging capabilities or the RACC project, contact Patrick Treado at treado[.]chemimage.com.

About ChemImage

ChemImage Corporation (chemimage.com), a leader in hyperspectral and Raman chemical imaging technology provides innovative instrumentation, analysis software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters are located in Pittsburgh, PA, where it pioneers research and development, as well as providing engineering and manufacturing which develops innovative products for the global marketplace.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ChemImage Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ChemImage Receives NIH Grant to Develop Blood Test for Early Detection of Colorectal Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tifanie Tiberio - ChemImage.com 
412-241-7335 x269 tiberiot[.]chemimage.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChemImage Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ChemImage Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)